Explore the frontier
Filter every story, video, company, game and lab experiment by topic, disease area, technology, company, development stage, format and audience.
24 results · 1 filter activeClear all
Genome + CellsCRISPR gene editing
A programmable molecular tool that cuts or changes DNA at a chosen address.
Genome + CellsCTX112 (zugocabtagene geleucel)
As of the company's Aug. 3, 2026 update, CTX112 is in Phase 1 basket trials across several autoimmune diseases (company release).
Genome + CellsCasgevy (exagamglogene autotemcel)
FDA-approved Dec. 8, 2023 for sickle cell disease (age 12+); CRISPR Therapeutics reported on Aug. 3, 2026 that the FDA extended approval to children 2 years and older.
Vertex Pharmaceuticals
Nasdaq: VRTXVertex develops small-molecule and genetic medicines for serious diseases and is best known for its cystic fibrosis drugs. It co-developed Casgevy, the…
Illumina
Nasdaq: ILMNIllumina makes DNA sequencing instruments, reagents and software used widely in research and clinical genomics. It acquired GRAIL in 2021 and separated…
Moderna
Nasdaq: MRNAModerna develops mRNA medicines and markets vaccines against COVID-19 and RSV. With Merck, it is developing intismeran autogene, an individualized neoantigen mRNA…
CRISPR Therapeutics
Nasdaq: CRSPCRISPR Therapeutics is a gene-editing company that co-developed Casgevy with Vertex. Its clinical pipeline includes in vivo editing programs for cardiovascular targets…
Genome + CellsDecode the Genome: What Sequencing Can Tell Us—and What It Cannot
From the $3 billion Human Genome Project to routine sequencing, reading DNA has become easy. Here is what a genome can reveal today, and where uncertain variants, risk scores and missing context set hard limits.
Genome + CellsGene Editing, Gene Therapy, and RNA Medicines: Three Different Ways to Change an Outcome
In December 2023 the FDA approved Casgevy, the first CRISPR-based therapy, for sickle cell disease. Here is how gene editing, gene therapy and RNA medicines differ, and what that approval does and doesn't prove.
LongevityThe Cell Health Frontier: Senescence, Mitochondria, and the Search for Better Healthspan
Some problems of ageing may start inside individual cells. This explainer tours senescence and mitochondria, from striking mouse results to small, mixed human trials, and explains why no therapy is yet approved to treat ageing.
DeepTech + MedTechBioprinting Human Tissue: What Works in the Lab, and What Would It Take to Reach Patients?
No bioprinted solid organ has been transplanted into a person, but bioprinting has produced striking lab and animal results. Here is what works today, what has reached early human testing, and what still stands in the way.
DeepTech + MedTechOrganoids and Lab-Grown Models: Could They Improve How We Test Treatments?
Organoids and organ-on-a-chip systems let researchers test drugs on human tissue models before people. The early evidence is promising but specific, and the models still miss much of real human biology.